StreetAlpha.app
Home › Stocks › VKTX

Viking Therapeutics, Inc. (VKTX)

Healthcare
$26.88
▲ +0.30%
LAST CLOSE · NOV 17

Viking Therapeutics develops drug candidates for obesity, fatty liver disease and a rare inherited brain and nerve disorder. It last closed at $26.88 on Nov 17, up 0.30% on the day. VKTX reports earnings on Wed, Feb 10, 2027. The average 12-month price target from 3 analysts is $99.00 (+268.3% from the last close), with a high of $118.00 and a low of $85.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in VKTX, 0% of them bullish and 100% bearish.

AI Auto Pilots
Is VKTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$627.2M
EPS (diluted)
−$5.42
Valuation
Market cap
$3.4B
127.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$677.6M
At Sep 30
Debt
$250.7M
At Sep 30
Shareholder equity
$588.6M
Shares outstanding
127.5M
At Oct 15
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From VKTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Feb 10
2027 · Time not announced
Consensus EPS forecast
-$1.38
 
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on VKTX in the past 90 days
Average 12-month target
$99.00
▲ 268.3% upside

Based on 3 analysts who set a price target on VKTX in the past 90 days. The average target is $99.00, with a high of $118.00 and a low of $85.00, compared with the last close of $26.88.

$17$53$89$126PAST 97 TRADING DAYS12-MONTH TARGETSHIGH $118AVG $99LOW $85May 26LAST CLOSE+12 MO$17$53$89$126PAST 97 DAYSTARGETSHIGH $118AVG $99LOW $85May 26LAST CLOSE+12 MO
Highest target$118.00
Average target$99.00
Lowest target$85.00
Latest rating changes
Canaccord GenuityTarget raised
Oct 31Buy$106 → $118
Canaccord GenuityTarget lowered
Oct 20Buy$114 → $106
UBSInitiated
Oct 15Buy$94
Truist SecuritiesTarget lowered
Oct 7Buy$87 → $85
Truist SecuritiesMaintained
Sep 23Buy$87
DateFirmActionRatingPrice target
Oct 31Canaccord GenuityTarget raisedBuy$106 → $118
Oct 20Canaccord GenuityTarget loweredBuy$114 → $106
Oct 15UBSInitiatedBuy$94
Oct 7Truist SecuritiesTarget loweredBuy$87 → $85
Sep 23Truist SecuritiesMaintainedBuy$87
Loading…

Technical Analysis

VKTX · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 20% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 47). The nearest support is the 20 day average at $26.77, and the nearest resistance the Pivot at $27.28.

Short trendNeutral
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 7.1%/day
Key levels
$43.1052 week high+60.3%
$32.18100 day average+19.7%
$32.14200 day average+19.6%
$30.10Swing high (Nov 10)+12.0%
$29.0350 day average+8.0%
$28.09Pivot R1+4.5%
$27.28Pivot+1.5%
$26.88Last close
$26.7720 day average−0.4%
$26.07Pivot S1−3.0%
$25.37Swing low (Nov 5)−5.6%
$23.8252 week low−11.4%
Indicators
RSI (14)47.21Middle of its rangeNeutral
MACD-0.20Above its signal lineBullish
Stochastic57.3Middle of its rangeNeutral
ADX (14)14.4No clear trend
Williams %R-56.3Oversold below −80, overbought above −20Neutral
CCI (20)30.4Oversold below −100, overbought above 100Neutral
Rate of change+3.0%Change over 10 sessionsBullish
ATR (14)$1.90Typical daily range, 7.1% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for VKTX

What happened before

See how VKTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow VKTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How VKTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Oct 13 – Oct 13
Loading…

See today’s whale options flow across the market →

VKTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲243 buying vs 191 selling
  • ▲Held by funds +14.8 pts
  • ▲Funds holding +8
  • ▼Superinvestors: 1 added, 3 cut
  • ▼Put/call 0.16 to 0.48
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding444436+1.8%
In funds' top 1085+60.0%
Held by funds74.4%59.6%+14.8 pts
New / increased82 / 16169 / 146+13.0%
Reduced / sold out125 / 66128 / 53+5.5%
Put/call ratio0.480.16+190.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VKTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VKTX is in one of them and how their past VKTX trades turned out.

VKTX in the AI portfolios
Loading…

VKTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VKTX in an article yet. Here's the latest on the wider market.

About Viking Therapeutics

Viking Therapeutics is a biopharmaceutical company based in San Diego, California, that develops drug candidates for metabolic and endocrine conditions. Its lead program, VK2735, is being studied as both an injectable and an oral tablet for obesity. The company is also developing VK2809 for fatty liver disease, known as NASH or MASH, and VK0214 for adrenoleukodystrophy, a rare inherited disorder that affects the brain and nerves. Its programs are in clinical development.

Headquarters
San Diego, CA